Ward Caleb L, Rojas Castro Madelyn Yiseth, Chakhunashvili Giorgi, Chitadze Nazibrola, Finci Iris, Pebody Richard, Kissling Esther, Katz Mark A, Sanodze Lia
Public Health Institute, Tbilisi, Georgia.
Epiconcept, Paris, France.
PLoS One. 2025 May 21;20(5):e0311337. doi: 10.1371/journal.pone.0311337. eCollection 2025.
Understanding COVID-19 vaccine effectiveness (VE) in healthcare workers (HCWs) is critical to inform vaccination policies. We measured COVID-19 VE against laboratory-confirmed symptomatic infection in HCWs in the country of Georgia from January - June 2022, during a period of Omicron circulation.
We conducted a cohort study of HCWs in six hospitals in Georgia. HCWs were enrolled in early 2021. Participants completed weekly symptom questionnaires. Symptomatic HCWs were tested by RT-PCR and/or rapid antigen test (RAT). Participants were also routinely tested, at varying frequencies during the study period, for SARS-CoV-2 by RT-PCR or RAT, regardless of symptoms. Serology was collected quarterly throughout the study and tested by electrochemiluminescence immunoassay for SARS-CoV-2 antibodies. We estimated absolute and relative VE of a first booster dose compared to a primary vaccine series as (1-hazard ratio)*100 using Cox proportional hazards models.
Among 1253 HCWs, 141 (11%) received a primary vaccine series (PVS) and a first booster, 855 (68%) received PVS only, and 248 (20%) were unvaccinated. Most boosters were BNT162b2 (Comirnaty original monovalent) vaccine (90%) and BBIBP-CorV vaccine (Sinopharm) (9%). Most PVS were BNT162b2 vaccine (68%) and BBIBP-CorV vaccine (24%). Absolute VE for a first booster was 40% (95% Confidence Interval (CI) -56-77) at 7-29 days following vaccination, -9% (95% CI -104-42) at 30-59 days following vaccination, and -46% (95% CI -156-17) at ≥ 60 days following vaccination. Relative VE of first booster dose compared to PVS was 58% (95% CI 1-82) at 7-29 days following vaccination, 21% (95% CI -33-54) at 30-59 days following vaccination, and -9% (95% CI -82-34) at ≥ 60 days following vaccination.
In Georgia, first booster dose VE against symptomatic SARS-CoV-2 infection among HCWs was moderately effective but waned very quickly during Omicron. Increased efforts to vaccinate priority groups in Georgia, such as healthcare workers, prior to periods of anticipated high COVID-19 incidence are essential.
了解医护人员中新冠病毒疫苗的有效性对于制定疫苗接种政策至关重要。我们在2022年1月至6月奥密克戎毒株传播期间,对格鲁吉亚国医护人员中针对实验室确诊的有症状感染的新冠病毒疫苗有效性进行了测量。
我们在格鲁吉亚的六家医院对医护人员进行了一项队列研究。医护人员于2021年初入组。参与者每周完成症状调查问卷。有症状的医护人员通过逆转录聚合酶链反应(RT-PCR)和/或快速抗原检测(RAT)进行检测。在研究期间,无论有无症状,参与者还定期以不同频率通过RT-PCR或RAT检测是否感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。在整个研究过程中每季度采集血清样本,并通过电化学发光免疫分析法检测SARS-CoV-2抗体。我们使用Cox比例风险模型,将第一剂加强针与初始疫苗系列相比的绝对和相对疫苗有效性估计为(1 - 风险比)*100。
在1253名医护人员中,141人(11%)接种了初始疫苗系列(PVS)和第一剂加强针,855人(68%)仅接种了PVS,248人(20%)未接种疫苗。大多数加强针为BNT162b2(Comirnaty原单价)疫苗(90%)和BBIBP - CorV疫苗(国药集团)(9%)。大多数PVS为BNT162b2疫苗(68%)和BBIBP - CorV疫苗(24%)。接种第一剂加强针后的绝对疫苗有效性在接种后7 - 29天为40%(95%置信区间(CI) -56 - 77),接种后30 - 59天为 -9%(95% CI -104 - 42),接种后≥60天为 -46%(95% CI -156 - 17)。第一剂加强针与PVS相比的相对疫苗有效性在接种后7 - 29天为58%(95% CI 1 - 82),接种后30 - 59天为21%(95% CI -33 - 54),接种后≥60天为 -9%(95% CI -82 - 34)。
在格鲁吉亚,医护人员中第一剂加强针对有症状的SARS-CoV-2感染的疫苗有效性在奥密克戎毒株期间中等有效,但迅速下降。在预计新冠病毒高发病率时期之前,加大力度为格鲁吉亚的优先群体(如医护人员)接种疫苗至关重要。